11,101 Shares in Zoetis Inc. $ZTS Purchased by Inceptionr LLC

Inceptionr LLC acquired a new position in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 11,101 shares of the company’s stock, valued at approximately $1,397,000.

Several other institutional investors have also bought and sold shares of the stock. Norges Bank acquired a new stake in Zoetis in the 4th quarter valued at about $734,425,000. Vanguard Group Inc. lifted its holdings in Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after acquiring an additional 5,474,210 shares during the last quarter. Nordea Investment Management AB lifted its holdings in Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after acquiring an additional 2,179,578 shares during the last quarter. Montrusco Bolton Investments Inc. lifted its holdings in Zoetis by 256.7% in the 4th quarter. Montrusco Bolton Investments Inc. now owns 2,168,078 shares of the company’s stock valued at $266,888,000 after acquiring an additional 1,560,314 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Zoetis by 83.4% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock valued at $394,746,000 after acquiring an additional 1,227,085 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Bank of America Securities reportedly maintained a Hold rating on Zoetis, which may provide some support by suggesting analysts are not turning more negative on the stock. Bank of America Securities Remains a Hold on Zoetis (ZTS)
• Neutral Sentiment: Some commentary notes that Zoetis may look inexpensive, but frames that valuation in the context of weaker fundamentals and legal concerns, making the stock’s appeal less clear-cut. Zoetis Might Be Cheap For A Reason
• Negative Sentiment: Multiple firms, including Rosen, Schall, DJS, and others, reiterated or promoted a securities-fraud class action against Zoetis, with deadlines for lead-plaintiff motions approaching. That ongoing litigation overhang is a clear negative for investor sentiment. Zoetis Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – ZTS

Zoetis Stock Performance

Shares of ZTS opened at $81.38 on Thursday. Zoetis Inc. has a one year low of $72.38 and a one year high of $168.83. The company has a 50-day moving average of $98.43 and a two-hundred day moving average of $114.75. The stock has a market cap of $34.12 billion, a price-to-earnings ratio of 13.50, a PEG ratio of 1.28 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the previous year, the business earned $1.48 earnings per share. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. UBS Group cut their price target on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Morgan Stanley reissued an “overweight” rating and issued a $115.00 price target on shares of Zoetis in a report on Friday, May 15th. Finally, BTIG Research reissued a “buy” rating and issued a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Six research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $133.92.

Insiders Place Their Bets

In other news, Director Paul Bisaro bought 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Frank A. Damelio bought 6,650 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the acquisition, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 11,650 shares of company stock worth $886,384 over the last ninety days. 0.22% of the stock is currently owned by company insiders.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.